达比加群酯(dabigatran etexilate)获得美国食品和药物管理局(FDA)批准用于预防非瓣膜性房颤患者卒中和全身性栓塞,是一种直接凝血酶抑制剂,口服经胃肠道吸收后迅速在肝及血浆中被酯酶水解释放出达比加群,后者选择性、可逆性地结合于凝血酶的纤维蛋白特异结合位点,阻止纤维蛋白原裂解为纤维蛋白,同时抑制凝血酶,阻止其介导的血小板活化、聚集和血栓形成,从而发挥 Dabigatran etexilate, approved by the U.S. Food and Drug Administration (FDA) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, is a direct thrombin inhibitor that is administered orally in the gastrointestinal tract It is rapidly hydrolyzed by esterases in the liver and plasma to release dabigatran, which selectively and reversibly binds to the fibrin-specific binding site of thrombin, preventing the cleavage of fibrinogen to fibrin, while inhibiting coagulation Enzymes, which prevent their mediation of platelet activation, aggregation and thrombosis, play